SG11202107762QA - Aflibercept attributes and methods of characterizing and modifying thereof - Google Patents

Aflibercept attributes and methods of characterizing and modifying thereof

Info

Publication number
SG11202107762QA
SG11202107762QA SG11202107762QA SG11202107762QA SG11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA
Authority
SG
Singapore
Prior art keywords
aflibercept
characterizing
attributes
modifying
methods
Prior art date
Application number
SG11202107762QA
Inventor
Quanzhou Luo
Diana Woehle
Matthew Jerums
Scott Kuhns
Xuejun Han
Kelli M G Matthies
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202107762QA publication Critical patent/SG11202107762QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202107762QA 2019-01-30 2020-01-29 Aflibercept attributes and methods of characterizing and modifying thereof SG11202107762QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962798903P 2019-01-30 2019-01-30
PCT/US2020/015659 WO2020160133A1 (en) 2019-01-30 2020-01-29 Aflibercept attributes and methods of characterizing and modifying thereof

Publications (1)

Publication Number Publication Date
SG11202107762QA true SG11202107762QA (en) 2021-08-30

Family

ID=69726812

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107762QA SG11202107762QA (en) 2019-01-30 2020-01-29 Aflibercept attributes and methods of characterizing and modifying thereof

Country Status (8)

Country Link
US (1) US20220098279A1 (en)
EP (1) EP3917951A1 (en)
JP (1) JP2022523063A (en)
AU (1) AU2020216368A1 (en)
CA (1) CA3127228A1 (en)
MX (1) MX2021008983A (en)
SG (1) SG11202107762QA (en)
WO (1) WO2020160133A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
MY190626A (en) * 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
WO2013075068A1 (en) * 2011-11-18 2013-05-23 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
KR20150038297A (en) * 2012-08-02 2015-04-08 사노피 Atricle of manufacture comprising aflibercept or ziv-aflibercept
MX2016004736A (en) * 2013-10-18 2016-07-26 Regeneron Pharma Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody.
EA202091598A3 (en) * 2014-12-01 2021-01-29 Эмджен Инк. THE PROCESS OF CONTROL OF THE CONTENT OF GLYCANS IN THE COMPOSITION
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein

Also Published As

Publication number Publication date
EP3917951A1 (en) 2021-12-08
AU2020216368A1 (en) 2021-08-12
WO2020160133A1 (en) 2020-08-06
CA3127228A1 (en) 2020-08-06
JP2022523063A (en) 2022-04-21
MX2021008983A (en) 2021-09-08
US20220098279A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
EP3645742A4 (en) Anti-ror1 antibodies and methods of making and using thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL290741A (en) Anti-cd96 antibodies and methods of use thereof
IL276285A (en) Activatable antibodies and methods of making and using thereof
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and their methods of use
IL288091A (en) Methods of characterizing and utilizing agent-condensate interactions
IL289829A (en) Immunomodulatory antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of use thereof
IL285117A (en) Methods of characterizing condensate-associated characteristics of compounds and uses thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
IL277212A (en) Anti-klk5 antibodies and methods of use
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
SG11202107762QA (en) Aflibercept attributes and methods of characterizing and modifying thereof
EP4061848A4 (en) Anti-ror-2 antibodies and methods of use
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
ZA202201160B (en) Anti-grp78 antibodies and method of use thereof